|
US3060165A
(en)
|
|
1962-10-23 |
|
Preparation of toxic ricin |
|
US498298A
(en)
|
|
1893-05-30 |
|
Range |
|
US4036945A
(en)
|
1976-05-03 |
1977-07-19 |
The Massachusetts General Hospital |
Composition and method for determining the size and location of myocardial infarcts
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4486414A
(en)
|
1983-03-21 |
1984-12-04 |
Arizona Board Of Reagents |
Dolastatins A and B cell growth inhibitory substances
|
|
US4957735A
(en)
|
1984-06-12 |
1990-09-18 |
The University Of Tennessee Research Corporation |
Target-sensitive immunoliposomes- preparation and characterization
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US5079163A
(en)
|
1985-03-29 |
1992-01-07 |
Cetus Corporation |
Recombinant ricin toxin fragments
|
|
US4689401A
(en)
|
1986-03-06 |
1987-08-25 |
Cetus Corporation |
Method of recovering microbially produced recombinant ricin toxin a chain
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4892827A
(en)
|
1986-09-24 |
1990-01-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US4816444A
(en)
|
1987-07-10 |
1989-03-28 |
Arizona Board Of Regents, Arizona State University |
Cell growth inhibitory substance
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
US5792458A
(en)
|
1987-10-05 |
1998-08-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Mutant diphtheria toxin conjugates
|
|
US5208021A
(en)
|
1987-10-05 |
1993-05-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of preparing diphtheria immunotoxins
|
|
CA1323293C
(en)
|
1987-12-11 |
1993-10-19 |
Keith C. Backman |
Assay using template-dependent nucleic acid probe reorganization
|
|
ATE138106T1
(de)
|
1988-07-20 |
1996-06-15 |
David Segev |
Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
|
|
US5076973A
(en)
|
1988-10-24 |
1991-12-31 |
Arizona Board Of Regents |
Synthesis of dolastatin 3
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US4978744A
(en)
|
1989-01-27 |
1990-12-18 |
Arizona Board Of Regents |
Synthesis of dolastatin 10
|
|
US5055303A
(en)
|
1989-01-31 |
1991-10-08 |
Kv Pharmaceutical Company |
Solid controlled release bioadherent emulsions
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US4879278A
(en)
|
1989-05-16 |
1989-11-07 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
|
|
US4986988A
(en)
|
1989-05-18 |
1991-01-22 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
US5138036A
(en)
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
|
US5188837A
(en)
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
|
US5427930A
(en)
|
1990-01-26 |
1995-06-27 |
Abbott Laboratories |
Amplification of target nucleic acids using gap filling ligase chain reaction
|
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
DK0531434T3
(da)
|
1990-05-11 |
2000-01-31 |
Us Health |
Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet
|
|
US5608039A
(en)
|
1990-10-12 |
1997-03-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Single chain B3 antibody fusion proteins and their uses
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
US5643578A
(en)
|
1992-03-23 |
1997-07-01 |
University Of Massachusetts Medical Center |
Immunization by inoculation of DNA transcription unit
|
|
DE69311538D1
(de)
|
1992-03-12 |
1997-07-17 |
Alkermes Inc |
Acth enthaltende mikrokugeln mit gesteuerter abgabe
|
|
WO1993025690A1
(en)
|
1992-06-18 |
1993-12-23 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant pseudomonas exotoxin with increased activity
|
|
US5534496A
(en)
|
1992-07-07 |
1996-07-09 |
University Of Southern California |
Methods and compositions to enhance epithelial drug transport
|
|
US5662907A
(en)
|
1992-08-07 |
1997-09-02 |
Cytel Corporation |
Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
|
|
EP0671926B1
(en)
|
1992-08-11 |
2002-11-13 |
President And Fellows Of Harvard College |
Immunomodulatory peptides
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5410024A
(en)
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
US5648211A
(en)
|
1994-04-18 |
1997-07-15 |
Becton, Dickinson And Company |
Strand displacement amplification using thermophilic enzymes
|
|
ES2168380T3
(es)
|
1994-07-15 |
2002-06-16 |
Organon Teknika Bv |
Utilizacion de arn polimerasa para mejorar un procedimiento de amplificacion de acido nucleico.
|
|
US5504191A
(en)
|
1994-08-01 |
1996-04-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide methyl esters
|
|
US5521284A
(en)
|
1994-08-01 |
1996-05-28 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides and esters
|
|
US5530097A
(en)
|
1994-08-01 |
1996-06-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory peptide amides
|
|
US5554725A
(en)
|
1994-09-14 |
1996-09-10 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Synthesis of dolastatin 15
|
|
US5599902A
(en)
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
ES2153031T4
(es)
|
1995-04-20 |
2001-05-16 |
Pfizer |
Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
AT402203B
(de)
|
1995-06-13 |
1997-03-25 |
Himmler Gottfried Dipl Ing Dr |
Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
|
EA199900021A1
(ru)
|
1996-07-13 |
1999-08-26 |
Глаксо, Груп Лимитед |
Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
KR20000067904A
(ko)
|
1996-07-18 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
매트릭스 메탈로프로테아제의 포스피네이트계 억제제
|
|
TW328661B
(en)
|
1996-07-26 |
1998-03-21 |
Oki Electric Ind Co Ltd |
The semiconductor apparatus
|
|
KR20000068248A
(ko)
|
1996-08-23 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
아릴설포닐아미노 하이드록삼산 유도체
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
JP3338064B2
(ja)
|
1997-01-06 |
2002-10-28 |
ファイザー・インク |
環状スルホン誘導体
|
|
NZ336840A
(en)
|
1997-02-03 |
2001-01-26 |
Pfizer Prod Inc |
Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
EP0960098A1
(en)
|
1997-02-11 |
1999-12-01 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
WO1998036765A1
(en)
|
1997-02-25 |
1998-08-27 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
|
|
JP2002511852A
(ja)
|
1997-05-07 |
2002-04-16 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
|
|
JP2002501532A
(ja)
|
1997-05-30 |
2002-01-15 |
メルク エンド カンパニー インコーポレーテッド |
新規血管形成阻害薬
|
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
|
AU744939B2
(en)
|
1997-09-26 |
2002-03-07 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
WO1999022596A1
(en)
|
1997-11-03 |
1999-05-14 |
Long Roger H |
Attractants for trapping flies
|
|
EP1028964A1
(en)
|
1997-11-11 |
2000-08-23 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
DE19755016A1
(de)
|
1997-12-11 |
1999-06-17 |
Bayer Ag |
Substituierte 2,4-Diamino-1,3,5-triazine
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
US6296843B1
(en)
|
1998-04-03 |
2001-10-02 |
The Penn State Research Foundation |
Mutagenized IL 13-based chimeric molecules
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
SK287132B6
(sk)
|
1998-05-29 |
2009-12-07 |
Sugen, Inc. |
Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
|
|
US6323315B1
(en)
|
1999-09-10 |
2001-11-27 |
Basf Aktiengesellschaft |
Dolastatin peptides
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
KR20060034231A
(ko)
|
2003-06-06 |
2006-04-21 |
메디뮨 인코포레이티드 |
암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
|
|
CN101227921A
(zh)
*
|
2003-06-06 |
2008-07-23 |
医学免疫公司 |
EphA4和EphA4调节剂用于诊断、治疗和预防癌症的用途
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
EP1733047A2
(en)
*
|
2004-02-27 |
2006-12-20 |
Oncotherapy Science, Inc. |
Pin-prc transition genes
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
ES2372537T3
(es)
|
2005-07-29 |
2012-01-23 |
The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services |
Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
|
|
CN101309933A
(zh)
*
|
2005-09-07 |
2008-11-19 |
米迪缪尼有限公司 |
毒素偶联的Eph受体抗体
|
|
US8003098B2
(en)
|
2006-02-28 |
2011-08-23 |
Oncotherapy Science, Inc. |
Methods for damaging cells using effector functions of anti-EphA4 antibodies
|
|
WO2009032954A1
(en)
|
2007-09-04 |
2009-03-12 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
|
|
JP2010285413A
(ja)
*
|
2009-06-10 |
2010-12-24 |
Univ Of Melbourne |
治療用途
|
|
WO2010141974A1
(en)
*
|
2009-06-10 |
2010-12-16 |
The University Of Melbourne |
Therapeutic applications
|
|
ES2544805T3
(es)
|
2009-09-11 |
2015-09-04 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida
|
|
JP2013505944A
(ja)
|
2009-09-24 |
2013-02-21 |
シアトル ジェネティックス， インコーポレイテッド |
Ｄｒ５リガンド薬物結合体
|
|
US20110212088A1
(en)
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
|
JP6059017B2
(ja)
*
|
2010-12-17 |
2017-01-11 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法
|
|
CA2918340C
(en)
*
|
2013-07-17 |
2023-01-03 |
The Hong Kong University Of Science And Technology |
Rhynchophylline derivatives and their use as epha4 inhibitors for neuroprotection
|
|
EP3331551B1
(en)
*
|
2015-07-10 |
2021-06-23 |
The Hong Kong University of Science and Technology |
Compositions for use in treating neurodegenerative and neuroinflammatory conditions
|
|
CN110769828A
(zh)
*
|
2017-05-12 |
2020-02-07 |
香港科技大学 |
作为epha4抑制剂的杂环化合物
|